Antimetabolites, Antineoplastic clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Irvine, California and other locations